开放期刊系统

卵巢早衰诊疗进展：机制解析与临床应用前景综述

马玉兰*, 丁亚倩

摘要

卵巢早衰（Premature Ovarian Failure, POF）或称为早发性卵巢功能不全（Premature Ovarian Insufficiency, POI），是指女性在40岁之前卵巢功能衰竭的病症，表现为月经停止、雌激素水平下降以及卵巢储备减少，这不仅对女性的生育能力造成严重影响，还对其身心健康构成威胁。近年来，随着生物医学技术的快速发展，卵巢早衰的研究不断深入，但仍存在许多未解之谜。本文综述了卵巢早衰的发病机制、诊断标志物、免疫学特征、分子调控、干细胞治疗、药物干预及辅助生殖技术等方面的最新研究进展。特别重点分析了非编码RNA、细胞凋亡、氧化应激、自噬及炎症反应在卵巢早衰中的重要作用，探讨了干细胞移植及生物活性物质的治疗潜力。通过系统整合最新的临床与基础研究成果，旨在为卵巢早衰的早期诊断和个体化治疗提供理论依据和实践指导。

关键词

卵巢早衰；早发性卵巢功能不全；非编码RNA；干细胞治疗；氧化应激；免疫炎症；辅助生殖技术；分子机制

全文:

PDF

参考

[1]Li Y, Zhang H, Cai C, et al.Microfluidic Encapsulation of Exosomes Derived from Lipopolysaccharide-Treated Mesenchymal Stem Cells in Hyaluronic Acid Methacryloyl to Restore Ovarian Function in Mice. Adv Healthc Mater. 2024;13(6):e2303068.

[2]Singhal P, Singh S, Kumar P, et al. Premature Ovarian Failure Related to Trisomy X: Two Case Reports with an Aberrant 47, XXX Karyotype. J Hum Reprod Sci. 2021 Jan-Mar;14(1):87-90.

[3]Zhang CR, Zhu WN, Tao W, et al.Moxibustion against Cyclophosphamide-Induced Premature Ovarian Failure in Rats through Inhibiting NLRP3-/Caspase-1-/GSDMD-Dependent Pyroptosis. Evid Based Complement Alternat Med. 2021:8874757. Published 2021 None.

[4]Tan Z, Gong X, Li Y, et al. Impacts of endometrioma on ovarian aging from basic science to clinical management. Front Endocrinol (Lausanne). 13:1073261. Published 2022 None.

[5]Lu Y, Yao Y, Zhai S, et al. The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on Mendelian randomization. Int J Surg. 2024;110(10):6541-6550. Published 2024 Oct 1.

[6]Persico T, Tranquillo ML, Seracchioli R, et al. PGT-M for Premature Ovarian Failure Related to CGG Repeat Expansion of the FMR1 Gene. Genes (Basel). 2023;15(1). Published 2023 Dec 19.

[7]Gao X, Jin Y, Zhang G. Systematic Review and Meta-Analysis: Impact of Various Hemostasis Methods on Ovarian Reserve Function in Laparoscopic Cystectomy for Ovarian Endometriomas. Altern Ther Health Med. 2024;30(8):312-319.

[8]Bravo P, Liu Y, Draper BW, et al. Macrophage activation drives ovarian failure and masculinization. bioRxiv..Published 2023 Jan 3.

[9]Wang Y, Teng X, Liu J. Research Progress on the Effect of Traditional Chinese Medicine on Signal Pathway Related to Premature Ovarian Insufficiency. Evid Based Complement Alternat Med. 2022:7012978. Published 2022 None.

[10]黄仟润,王风笛,陈月璐,等.免疫因素与POI发病的相关研究进展[J].重庆医科大学学报,2025,50(01):19-22.

[11]Luo J, Sun Z. MicroRNAs in POI, et al. Arch Gynecol Obstet. 2023;308(5):1419-1430. doi:10.1007/s00404-023-06922-z

[12]Ghasroldasht MM, Park HS, Ali FL, et al. Adapted Exosomes for Addressing Chemotherapy-induced Premature Ovarian Insufficiency. Stem Cell Rev Rep. 2025;21(3):779-796.

[13]Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng. :1-2. Published online Apr 12,2023.

[14]于洋,张艺川.间充质干细胞外泌体与卵巢功能减退治疗[J].中国实用妇科与产科杂志,2025,41(05):525-533.

[15] Doamekpor LA, Head SK, South E, et al.Determinants of Hormone Replacement Therapy Knowledge and Current Hormone Replacement Therapy Use. J Womens Health (Larchmt). 2023;32(3):283-292.

[16]Burns BR. Hormone Therapy: Aging-Related Hormone Replacement Therapy and Supplementation. FP Essent. 531:22-26.

[17]Chen X, Li B. How nature incorporates sulfur and selenium into bioactive natural products. Curr Opin Chem Biol. 76:102377.

[18]Luan YY, Zhang L, Peng YQ, et al. Immune regulation in polycystic ovary syndrome. Clin Chim Acta. 531:265-272.

[19]Morimoto H, Tsujikawa T, Miyagawa-Hayashino A, et al. Neutrophil-to-lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma. Head Neck. 2024;46(8):1956-1964.

[20]Afkhami F, Shahbazi S, Farzadi L, et al. Novel bone morphogenetic protein 15 (BMP15) gene variants implicated in premature ovarian insufficiency. Reprod Biol Endocrinol. 2022;20(1):42. Published 2022 Mar 1.

[21]Fattet AJ, Toupance S, Thornton SN, et al. Telomere length in granulosa cells and leukocytes: a potential marker of female fertility? A systematic review of the literature. J Ovarian Res. 2020;13(1):96. Published 2020 Aug 21.

[22]Moustaki M, Kontogeorgi A, Tsangkalova G, et al. Biological therapies for premature ovarian insufficiency: what is the evidence? Front Reprod Health. 5:1194575. Published 2023 None.

[23]Zhang Y, Zhou X, Zhu Y, et al. Current mechanisms of primordial follicle activation and new strategies for fertility preservation. Mol Hum Reprod. 2021;27(2).

[24]Zhang Y, Liu H, Lou Y, et al. Efficacy and safety of autologous adipose tissue-derived stromal vascular fraction in patients with premature ovarian insufficiency: protocol for a single-centre randomised controlled trial. BMJ Open. 2025;15(4):e093804.Published 2025 Apr 3.

[25]Zhao X, Yu Z, Wang X, et al. The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical. Gynecol Endocrinol. 2024;40(1):2382818.

[26]Seracchioli R, Maletta M, Pazzaglia E, et al.Ovarian tissue biopsy for cryopreservation by vaginal natural orifice transluminal endoscopic surgery: a new approach for a minimal invasive ovarian biopsy. Fertil Steril. 2024;122(2):385-387.

[27]Jambarsang S, Khodayarian M, Sefidkar R, et al. Prevalence of premature ovarian insufficiency (POI) and its relationship with female reproductive factors in Iranian women: a cross-sectional study from the Persian (Shahedieh) cohort data. BMC Womens Health. 2023;23(1):467. Published 2023 Sep 1.

[28]阮祥燕.医源性早发性卵巢功能不全临床治疗与管理指南(2025年版)[J].中国实用妇科与产科杂志,2025,41(01):76-87.DOI:10.19538/j.fk2025010120

[29]Evangelinakis N, Geladari EV, Geladari CV, et al.The influence of environmental factors on premature ovarian insufficiency and ovarian aging. Maturitas. 179:107871.

(1 摘要 Views, 6 PDF Downloads)

Refbacks

当前没有refback。

用户名
密码
记住我